- Over 60% of product development failures are execution failures, not innovation failures
- The innovation-execution gap widens when strategy and operations teams work in silos
- A structured "innovation funnel" with defined stage-gates prevents resource dilution
- The most commercially successful companies invest equally in execution capability and R&D
A persistent myth in the life sciences industry is that commercial failure stems from insufficient innovation. In reality, more than 60% of product development failures can be traced not to the quality of the science, but to failures in execution - poor project governance, misaligned commercial and R&D priorities, inadequate operational planning, and an inability to translate scientific promise into market-ready products efficiently.
Most pharmaceutical and nutraceutical companies maintain large innovation pipelines with dozens of concepts at various stages of development. However, without a structured funnel management process - with clear selection criteria, resource allocation rules, and go/no-go gates - these pipelines become innovation graveyards: projects that consume resources without ever reaching commercialisation. The result is organisational exhaustion, budget overruns, and missed market windows.
The innovation-execution gap is fundamentally an organisational alignment problem. R&D teams optimise for scientific novelty; commercial teams optimise for speed-to-revenue; operations teams optimise for process reliability. When these three functions operate in silos - which is the default in most mid-sized companies - innovation efforts are consistently undermined by operational and commercial realities that were never incorporated into the development plan.
The solution is not to reduce innovation ambition, but to build execution capacity at the same pace. This means implementing cross-functional project teams from concept stage, building operational readiness checkpoints into the R&D process, and creating feedback loops between commercial performance and innovation priorities. Companies that achieve this balance consistently outperform their peers on time-to-market, product success rate, and return on R&D investment.
At SCPS Experts, we apply a three-lens framework to assess and improve the innovation-execution balance: (1) Pipeline quality - are you investing in the right ideas? (2) Process robustness - do you have the operational systems to execute reliably? (3) Organisational alignment - are your teams structured and incentivised to collaborate across the development-to-launch value chain? Strengthening all three simultaneously is the foundation of sustained commercial performance.